Display options
Cite
Faulkner MA. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. Ther Clin Risk Manag. 2015;11:905-14doi: 10.2147/TCRM.S55930.
Faulkner, M. A. (2015). Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. Therapeutics and clinical risk management, 11905-14. https://doi.org/10.2147/TCRM.S55930
Faulkner, Michele A. "Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome." Therapeutics and clinical risk management vol. 11 (2015): 905-14. doi: https://doi.org/10.2147/TCRM.S55930
Faulkner MA. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. Ther Clin Risk Manag. 2015 Jun 08;11:905-14. doi: 10.2147/TCRM.S55930. eCollection 2015. PMID: 26089675; PMCID: PMC4467745.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2015 Jun 08;11:905-14. doi: 10.2147/TCRM.S55930. eCollection 2015.

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.

Therapeutics and clinical risk management

Michele A Faulkner

Affiliations

  1. Department of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE, USA ; Department of Neurology, Creighton University School of Medicine, Omaha, NE, USA.

PMID: 26089675 PMCID: PMC4467745 DOI: 10.2147/TCRM.S55930

Abstract

Clobazam is the newest medication approved by the US Food and Drug Administration (FDA) for the treatment of Lennox-Gastaut syndrome (LGS) in patients at least 2 years of age, although the medication has been available in countries around the world to treat epilepsy and anxiety disorders for many years. Though classified as a benzodiazepine, the drug differs structurally from other drugs in the class as it possesses nitrogen atoms at the 1 and 5 positions within the heterocyclic ring rather than at the 1 and 4 positions. This difference and the classification of clobazam as a partial agonist are believed to be responsible for the decreased incidence of sedative effects compared to other benzodiazepines. Adverse events associated with clobazam use in clinical trials have generally been mild to moderate in nature. Data from an open-label extension trial have confirmed that clobazam is efficacious for the treatment of seizures associated with LGS, particularly atonic seizures (drop seizures), over the long term. Tolerance to the drug's antiepileptic effects does not seem to be a common occurrence. The drug has proven to be a cost-effective option for therapy, particularly due to its ability to decrease the number of seizures that require medical treatment. Clobazam represents a welcome addition to the treatment options for LGS.

Keywords: Lennox–Gastaut syndrome; clobazam; drop seizures

References

  1. Drug Saf. 2000 Jun;22(6):467-77 - PubMed
  2. Epilepsia. 1978 Jun;19(3):293-9 - PubMed
  3. Br Med J (Clin Res Ed). 1981 Sep 5;283(6292):643-5 - PubMed
  4. Epilepsia. 2011 Aug;52 Suppl 5:3-9 - PubMed
  5. Br J Clin Pharmacol. 1979;7 Suppl 1:85S-90S - PubMed
  6. Eur J Pharmacol. 2011 Mar 5;654(2):160-5 - PubMed
  7. Br J Clin Pharmacol. 1979;7 Suppl 1:51S-57S - PubMed
  8. CNS Drugs. 2012 Mar 1;26(3):229-44 - PubMed
  9. J Child Neurol. 2002 Jan;17 Suppl 1:S70-5 - PubMed
  10. J Child Neurol. 2010 Apr;25(4):441-7 - PubMed
  11. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005194 - PubMed
  12. Brain Res Mol Brain Res. 2005 Dec 14;142(2):91-6 - PubMed
  13. Epilepsia. 2014 Apr;55(4):558-67 - PubMed
  14. Nature. 1999 Oct 21;401(6755):796-800 - PubMed
  15. Neuropsychiatr Dis Treat. 2011;7:673-81 - PubMed
  16. Epilepsy Behav. 2013 Oct;29(1):184-9 - PubMed
  17. Epileptic Disord. 2007 Dec;9(4):353-412 - PubMed
  18. Neurotherapeutics. 2014 Oct;11(4):796-806 - PubMed
  19. Neurology. 1999 May 12;52(8):1540-5 - PubMed
  20. Neurotherapeutics. 2007 Jan;4(1):138-44 - PubMed
  21. J Manag Care Spec Pharm. 2014 Apr;20(4):400-6 - PubMed
  22. Epilepsia. 1986;27 Suppl 1:S27-41 - PubMed
  23. J Child Neurol. 2013 Feb;28(2):219-29 - PubMed
  24. Epilepsy Behav. 2012 Dec;25(4):687-94 - PubMed
  25. Lancet Neurol. 2009 Jan;8(1):82-93 - PubMed
  26. JAMA. 2001 Aug 15;286(7):821-30 - PubMed
  27. Pharmacol Toxicol. 1990 Aug;67(2):136-40 - PubMed
  28. Epilepsy Behav. 2014 Dec;41:47-52 - PubMed
  29. MMWR Surveill Summ. 2008 Aug 8;57(6):1-20 - PubMed
  30. Pharmacogenomics. 2008 May;9(5):527-37 - PubMed
  31. Epilepsia. 2014 Sep;55 Suppl 4:4-9 - PubMed
  32. Acta Neurol Scand. 2013 Aug;128(2):91-9 - PubMed
  33. Epileptic Disord. 2011 May;13 Suppl 1:S3-13 - PubMed
  34. J Child Neurol. 2004 Aug;19 Suppl 1:S25-38 - PubMed
  35. Pharmacoeconomics. 2010;28(3):185-99 - PubMed
  36. Expert Opin Pharmacother. 2012 Feb;13(2):227-33 - PubMed
  37. Brain Dev. 1991 May;13(3):174-9 - PubMed
  38. Pharmacotherapy. 2012 Apr;32(4):340-53 - PubMed
  39. Neurology. 2011 Oct 11;77(15):1473-81 - PubMed
  40. Epilepsia. 1999 Jul;40(7):985-91 - PubMed
  41. Br J Clin Pharmacol. 1979;7 Suppl 1:109S-112S - PubMed
  42. Epilepsia. 1979 Aug;20(4):437-46 - PubMed
  43. J Clin Neurophysiol. 2003 Nov-Dec;20(6):426-41 - PubMed
  44. Br J Clin Pharmacol. 1975 Jun;2(3):215-21 - PubMed
  45. Epilepsia. 2009 May;50(5):1158-66 - PubMed
  46. Epilepsy Behav. 2014 Aug;37:11-5 - PubMed
  47. Nat Neurosci. 2000 Jun;3(6):587-92 - PubMed
  48. Br Med J (Clin Res Ed). 1981 Jun 13;282(6280):1931-2 - PubMed

Publication Types